Oncoclinicas do Brasil (ONCO3) - Total Assets
Based on the latest financial reports, Oncoclinicas do Brasil (ONCO3) holds total assets worth R$8.22 Billion BRL (≈ $1.61 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ONCO3 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Oncoclinicas do Brasil - Total Assets Trend (2013–2024)
This chart illustrates how Oncoclinicas do Brasil's total assets have evolved over time, based on quarterly financial data. Check ONCO3 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Oncoclinicas do Brasil - Asset Composition Analysis
Current Asset Composition (December 2024)
Oncoclinicas do Brasil's total assets of R$8.22 Billion consist of 41.6% current assets and 58.4% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$472.62 Million | 4.9% |
| Accounts Receivable | R$2.05 Billion | 18.3% |
| Inventory | R$225.24 Million | 2.0% |
| Property, Plant & Equipment | R$1.34 Billion | 11.9% |
| Intangible Assets | R$1.35 Billion | 12.0% |
| Goodwill | R$2.40 Billion | 21.5% |
Asset Composition Trend (2013–2024)
This chart illustrates how Oncoclinicas do Brasil's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ONCO3 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncoclinicas do Brasil's current assets represent 41.6% of total assets in 2024, an increase from 35.9% in 2013.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2024, down from 5.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 40.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 21.5% of total assets.
Oncoclinicas do Brasil Competitors by Total Assets
Key competitors of Oncoclinicas do Brasil based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fresenius Medical Care AG & Co. KGaA
XETRA:FME
|
Germany | €31.47 Billion |
|
Ramsay Health Care Ltd
AU:RHC
|
Australia | AU$21.70 Billion |
|
PACS Group, Inc.
NYSE:PACS
|
USA | $5.66 Billion |
|
RAMSAY HLTH.CARE ADR/025
F:RMY0
|
Germany | €22.48 Billion |
|
Top Choice Medical Investment Co Inc
SHG:600763
|
China | CN¥6.24 Billion |
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
China | CN¥3.72 Billion |
|
Xian International Medical Investment Co Ltd
SHE:000516
|
China | CN¥9.50 Billion |
|
MLP Saglik Hizmetleri AS
IS:MPARK
|
Turkey | TL89.94 Billion |
Oncoclinicas do Brasil - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.96 | 1.40 |
| Quick Ratio | 1.06 | 1.87 | 1.36 |
| Cash Ratio | 0.06 | 0.21 | 0.00 |
| Working Capital | R$334.03 Million | R$2.44 Billion | R$406.05 Million |
Oncoclinicas do Brasil - Advanced Valuation Insights
This section examines the relationship between Oncoclinicas do Brasil's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 22.0% |
| Total Assets | R$11.20 Billion |
| Market Capitalization | $182.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncoclinicas do Brasil's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oncoclinicas do Brasil's assets grew by 22.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oncoclinicas do Brasil (2013–2024)
The table below shows the annual total assets of Oncoclinicas do Brasil from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | R$11.20 Billion ≈ $2.20 Billion |
+22.01% |
| 2023-12-31 | R$9.18 Billion ≈ $1.80 Billion |
+11.70% |
| 2022-12-31 | R$8.22 Billion ≈ $1.61 Billion |
+36.26% |
| 2021-12-31 | R$6.03 Billion ≈ $1.18 Billion |
+77.77% |
| 2020-12-31 | R$3.39 Billion ≈ $665.86 Million |
+60.81% |
| 2019-12-31 | R$2.11 Billion ≈ $414.07 Million |
+56.51% |
| 2018-12-31 | R$1.35 Billion ≈ $264.56 Million |
+71.45% |
| 2017-12-31 | R$786.42 Million ≈ $154.31 Million |
+27.03% |
| 2016-12-31 | R$619.07 Million ≈ $121.47 Million |
+18.49% |
| 2015-12-31 | R$522.46 Million ≈ $102.52 Million |
+44.75% |
| 2014-12-31 | R$360.93 Million ≈ $70.82 Million |
+12.64% |
| 2013-12-31 | R$320.43 Million ≈ $62.87 Million |
-- |
About Oncoclinicas do Brasil
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, ch… Read more